Shanghai RAAS(002252) Huafu Securities·2024-11-26 00:18Investment Rating - The report gives a "Buy" rating for the company, Shanghai Laishi [1][3]. Core Views - The blood products industry is highly concentrated, benefiting leading companies. The top six companies account for 70%-80% of domestic plasma collection, indicating a favorable environment for leading firms [1][2]. - The company has a strong position in the industry with 44 plasma collection stations and a collection volume of 1,500 tons in 2023, ranking it among the top players [1][2]. - Haier Group's acquisition of a 20% stake in the company is expected to enhance its long-term development through synergies with Haier's health sector [1][2]. - The extension of the exclusive agency agreement with Grifols for ten years provides strong certainty for the company's agency business [1][2]. Summary by Sections 1. Company Overview - Shanghai Laishi is a well-established blood products company, with a history dating back to 1988. It has expanded through mergers and acquisitions and currently operates five production bases [1][15]. - The company produces a wide range of blood products, including 12 varieties, and is the second-largest in the industry [1][15]. 2. Industry Dynamics - The blood products market in China is growing, with a market size exceeding 500 billion yuan. The market is expected to reach approximately 600 billion yuan by 2024 [1][34]. - The industry has high barriers to entry, with no new blood product manufacturers approved since 2001, leading to a concentrated market [1][34]. 3. Financial Performance - In 2023, the company achieved a revenue of 7.964 billion yuan, a year-on-year increase of 21.3%, while net profit was 1.779 billion yuan, a decrease of 5.4% [2][22]. - The company’s earnings per share (EPS) for 2024 is projected to be 0.35 yuan, with a net profit growth rate of 30% [2][22]. 4. Product and Revenue Breakdown - The company's revenue is primarily derived from its own products and the agency business for Grifols' albumin products. In 2023, agency albumin revenue was 3.5 billion yuan, a 28% increase [1][26]. - The gross margin for self-produced products is higher than that of agency products, with self-produced albumin having a gross margin of 46.2% in 2024H1 [1][56]. 5. Future Outlook - The company is expected to see continued growth in plasma collection and profitability, supported by Haier Group's strategic involvement and the extension of agency agreements [1][2].